- Bradikinin B2 receptor based drugs for angioedema and severe burn, drugs for ophthalmic disease indications
- Investment Period: 7 years
- 2005 IPO on the Frankfurt Stock Exchange
- 2008 Strategic Acquisition by Shire Limited
TVM Capital Partner Hubert Birner served on the Supervisory Board and was instrumental in M&A negotiation prior to the acquisition. He served as Vice Chairman of the Board throughout all the years of investment and led the company through several challenging situations include a senior management change over.